ReElement Technologies stock soars after securing $1.4B government deal
Investing.com - Needham raised its price target on Glaukos Corporation (NYSE:GKOS) to $117.00 from $115.00 on Thursday, while maintaining a Buy rating following the company’s third-quarter earnings report. The new target represents a 52% upside from the current price of $77.09, with Glaukos currently trading near its 52-week low of $73.16, according to InvestingPro data.
Glaukos reported better-than-expected revenue for the third quarter of 2025, with the company’s iDose product driving the performance. The strong results prompted management to increase its revenue guidance for the remainder of 2025. This continues the company’s impressive revenue growth trajectory, which InvestingPro data shows reached 26.7% over the last twelve months, despite the company not yet achieving profitability.
The medical technology company also provided revenue guidance for 2026 that aligned with market expectations. Additionally, Glaukos announced that its Epioxa treatment will have a wholesale acquisition cost (WAC) of $78,500. With a market capitalization of $4.42 billion and a strong current ratio of 5.51, the company appears well-positioned to support this product launch.
The company plans to phase out its Photrexa product over the course of 2026 as it transitions to Epioxa, which is scheduled for launch in the first quarter of 2026. Epioxa’s upcoming release is expected to be a significant revenue driver.
Needham cited continued adoption of the iDose treatment and expressed confidence in upcoming clinical data ahead of a CAC meeting scheduled for November 12, 2025, as key factors supporting its positive outlook on the stock.
In other recent news, Glaukos Corporation reported impressive third-quarter results, significantly surpassing earnings and revenue expectations. The company achieved a revenue of $133.5 million, marking a 38% increase compared to the previous year and exceeding the consensus estimate of $122.4 million. Glaukos also posted an earnings per share (EPS) of -$0.16, which was better than the anticipated -$0.26, delivering a 38.46% positive surprise. The revenue from its Glaucoma segment reached $110.2 million, with the iDose product contributing around $40 million. Following these robust results, BTIG raised its price target for Glaukos to $116 from $104, while maintaining a Buy rating. These developments highlight the company’s strong performance in the recent quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.